ReviewHuman vaccines & immunotherapeutics2026
A data-driven cartography of NSCLC vaccine research: Quantifying the paradigm shift toward immuno-oncology combination therapies.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic vaccine landscape for non-small cell lung cancer (NSCLC) has evolved substantially over the past three decades, yet systematic analysis of this progression remains limited. We conducted bibliometric analysis of NSCLC vaccine research using 765 publications spanning 1990-2025 from Web of Science and Scopus databases. Our temporal analysis revealed a marked paradigm shift from early investigations on single-antigen approaches (particularly MAGE-A3) and specific platforms such as BLP25 liposome vaccines toward combination strategies integrating immune checkpoint inhibitors (ICIs) and advanced RNA vaccine technologies. This reflects reorientation from standalone vaccine modalities to synergistic approaches combining vaccines with established therapeutics, including ICIs, targeted therapies, and antibody-drug conjugates. This bibliometric analysis provides the first systematic mapping of NSCLC vaccine research evolution, revealing a clear trajectory toward combination immunotherapy strategies and offering an evidence-based framework for identifying research priorities and informing future development directions in cancer vaccine research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.